(IPX) IperionX American - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: AU0000208910
Stock: Titanium, Zircon, Rare Earths, Metal Powder
Total Rating 47
Risk 68
Buy Signal -0.03
| Risk 5d forecast | |
|---|---|
| Volatility | 66.4% |
| Relative Tail Risk | -12.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.57 |
| Alpha | 124.48 |
| Character TTM | |
|---|---|
| Beta | 1.076 |
| Beta Downside | 1.570 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.86% |
| CAGR/Max DD | 1.73 |
Risks
Technicals:
volatile
Description: IPX IperionX American March 02, 2026
IperionX Limited (NASDAQ: IPX) is a U.S.-based developer of critical mineral assets, holding 100 % of the Titan project in Tennessee, which hosts titanium, zircon, and rare-earth resources. The firm also manufactures angular and spherical titanium metal powders for a broad set of end-markets, including automotive, aerospace, defense, energy, medical, consumer electronics, luxury goods, and industrial applications.
As of the latest Q2 2024 update, the Titan project disclosed measured and indicated resources of approximately 1.2 million tonnes of ilmenite-equivalent titanium, while titanium powder demand in the U.S. automotive sector rose 12 % year-over-year, driven by lightweight-vehicle initiatives. Concurrently, the U.S. Department of Energy has earmarked $150 million in 2024 for domestic critical-minerals supply chain development, underscoring a favorable policy backdrop for IPX’s assets.
For deeper analysis, consider checking ValueRay’s platform.
Headlines to watch out for
- Titanium metal powder production volume and sales prices
- Critical minerals project development and permitting progress
- Raw material costs for titanium and rare earth elements
- Demand for titanium across aerospace and automotive sectors
- Regulatory changes impacting critical minerals extraction
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.99 > 0.02 and ΔFCF/TA -96.28 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -23.9m > Net Income -70.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.5m) vs 12m ago 8.85% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -255.8 > 6 (EBITDA TTM -75.6m / Interest Expense TTM 307.1k) |
Altman Z'' 2.69
| A: 0.48 (Total Current Assets 58.9m - Total Current Liabilities 8.43m) / Total Assets 105.0m |
| B: -1.04 (Retained Earnings -109.2m / Total Assets 105.0m) |
| C: -0.71 (EBIT TTM -78.5m / Avg Total Assets 110.4m) |
| D: 7.34 (Book Value of Equity 92.4m / Total Liabilities 12.6m) |
| Altman-Z'' Score: 2.69 = A |
Beneish M
| DSRI: none (Receivables 823.3k/2.30m, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.58 (AQ_t 0.20 / AQ_t-1 0.13) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: -0.45 (NI -70.7m - CFO -23.9m) / TA 105.0m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of IPX shares?
As of March 11, 2026, the stock is trading at USD 50.26 with a total of 171,970 shares traded.
Over the past week, the price has changed by +5.70%, over one month by +14.62%, over three months by +38.19% and over the past year by +153.20%.
Over the past week, the price has changed by +5.70%, over one month by +14.62%, over three months by +38.19% and over the past year by +153.20%.
Is IPX a buy, sell or hold?
IperionX American has received a consensus analysts rating of 5.00.
Therefore, it is recommended to buy IPX.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IPX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 67.8 | 34.8% |
| Analysts Target Price | 67.8 | 34.8% |
IPX Fundamental Data Overview March 09, 2026
P/E Forward = 2500.0
P/B = 17.0471
Revenue TTM = 0.0 USD
EBIT TTM = -78.5m USD
EBITDA TTM = -75.6m USD
Long Term Debt = 3.46m USD (estimated: total debt 3.93m - short term 472.0k)
Short Term Debt = 472.0k USD (from shortTermDebt, last quarter)
Debt = 3.93m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -50.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.53b USD (1.58b + Debt 3.93m - CCE 54.8m)
Interest Coverage Ratio = -255.8 (Ebit TTM -78.5m / Interest Expense TTM 307.1k)
EV/FCF = -14.70x (Enterprise Value 1.53b / FCF TTM -104.1m)
FCF Yield = -6.80% (FCF TTM -104.1m / Enterprise Value 1.53b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.00m) / Revenue TTM)
Tobins Q-Ratio = 14.56 (Enterprise Value 1.53b / Total Assets 105.0m)
Interest Expense / Debt = 0.03% (Interest Expense 1323 / Debt 3.93m)
Taxrate = 21.0% (US default 21%)
NOPAT = -62.0m (EBIT -78.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.99 (Total Current Assets 58.9m / Total Current Liabilities 8.43m)
Debt / Equity = 0.04 (Debt 3.93m / totalStockholderEquity, last quarter 92.4m)
Debt / EBITDA = 0.67 (negative EBITDA) (Net Debt -50.9m / EBITDA -75.6m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -50.9m / FCF TTM -104.1m)
Total Stockholder Equity = 95.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -64.01% (Net Income -70.7m / Total Assets 105.0m)
RoE = -73.85% (Net Income TTM -70.7m / Total Stockholder Equity 95.7m)
RoCE = -79.18% (EBIT -78.5m / Capital Employed (Equity 95.7m + L.T.Debt 3.46m))
RoIC = -58.77% (negative operating profit) (NOPAT -62.0m / Invested Capital 105.6m)
WACC = 9.86% (E(1.58b)/V(1.58b) * Re(9.88%) + D(3.93m)/V(1.58b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.46%
[DCF] Fair Price = unknown (Cash Flow -104.1m)
EPS Correlation: 15.36 | EPS CAGR: 100.4% | SUE: 2.40 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS current Year (2026-06-30): EPS=-0.07 | Chg7d=-0.001 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=+40.8% | Growth Revenue=+0.0%
EPS next Year (2027-06-30): EPS=0.06 | Chg7d=+0.012 | Chg30d=+0.017 | Revisions Net=+1 | Growth EPS=+187.3% | Growth Revenue=+550.1%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
P/B = 17.0471
Revenue TTM = 0.0 USD
EBIT TTM = -78.5m USD
EBITDA TTM = -75.6m USD
Long Term Debt = 3.46m USD (estimated: total debt 3.93m - short term 472.0k)
Short Term Debt = 472.0k USD (from shortTermDebt, last quarter)
Debt = 3.93m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -50.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.53b USD (1.58b + Debt 3.93m - CCE 54.8m)
Interest Coverage Ratio = -255.8 (Ebit TTM -78.5m / Interest Expense TTM 307.1k)
EV/FCF = -14.70x (Enterprise Value 1.53b / FCF TTM -104.1m)
FCF Yield = -6.80% (FCF TTM -104.1m / Enterprise Value 1.53b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.00m) / Revenue TTM)
Tobins Q-Ratio = 14.56 (Enterprise Value 1.53b / Total Assets 105.0m)
Interest Expense / Debt = 0.03% (Interest Expense 1323 / Debt 3.93m)
Taxrate = 21.0% (US default 21%)
NOPAT = -62.0m (EBIT -78.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.99 (Total Current Assets 58.9m / Total Current Liabilities 8.43m)
Debt / Equity = 0.04 (Debt 3.93m / totalStockholderEquity, last quarter 92.4m)
Debt / EBITDA = 0.67 (negative EBITDA) (Net Debt -50.9m / EBITDA -75.6m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -50.9m / FCF TTM -104.1m)
Total Stockholder Equity = 95.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -64.01% (Net Income -70.7m / Total Assets 105.0m)
RoE = -73.85% (Net Income TTM -70.7m / Total Stockholder Equity 95.7m)
RoCE = -79.18% (EBIT -78.5m / Capital Employed (Equity 95.7m + L.T.Debt 3.46m))
RoIC = -58.77% (negative operating profit) (NOPAT -62.0m / Invested Capital 105.6m)
WACC = 9.86% (E(1.58b)/V(1.58b) * Re(9.88%) + D(3.93m)/V(1.58b) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.46%
[DCF] Fair Price = unknown (Cash Flow -104.1m)
EPS Correlation: 15.36 | EPS CAGR: 100.4% | SUE: 2.40 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS current Year (2026-06-30): EPS=-0.07 | Chg7d=-0.001 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=+40.8% | Growth Revenue=+0.0%
EPS next Year (2027-06-30): EPS=0.06 | Chg7d=+0.012 | Chg30d=+0.017 | Revisions Net=+1 | Growth EPS=+187.3% | Growth Revenue=+550.1%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)